BOSTON - A new RSV vaccine shows promise in preventing severe respiratory illness in seniors and infants. RSV is a virus that not only causes serious respiratory infection in infants, but in older adults as well. A new study in the New England Journal of Medicine found ...
A key advisory committee for the U.S. Food and Drug Administration recommended approval of the Pfizer vaccine for seniors last week, based on these clinical trial results. The committee also gave its nod to a competing RSV vaccine developed by GlaxoSmithKline. Pfizer expects an FDA decision on ...
Twitter Facebook Email Live Now CBS News 24/7 CBS News Baltimore CBS News Bay Area CBS News Boston CBS News Chicago CBS News Colorado CBS News Detroit CBS News Los Angeles Keller @ Large Boston City Councilor on housing crisis in Ma... ...
SAVVY SENIOR: ; New flu vaccine for seniors is high potencyJim Miller
One of the biggest culprits of serious viral illness in seniors will soon be rivaled by a powerful new vaccine, according to infectious disease authorities. The vaccine, which protects against respiratory syncytial virus (RSV), could be a game changer in preventing hospitalizations and de...
In people 60 and older, the vaccines reduced the risk of severe RSV by about 86%. How long will the new RSV vaccine protect elders and infants from RSV? For adults 60 and older, RSV vaccines are showing continued protection even two years after immunization. Based on this, the U.S. Ce...
Here’s the best time to get your annual vaccine BY Lindsey Leake September 3, 2024 Health New COVID vaccines are here. What to know about the latest shots as summer surge continues BY Lindsey Leake August 29, 2024 Health Moderna pauses its RSV vaccine trial for children after 5...
The RSV vaccine is not annual, meaning people who got one last year don’t need to get another one at this time, the CDC said. Those who didn’t can get it on the same visit as their flu and COVID shots. An RSV vaccine is also available for expectant ...
which just several weeks later nabbed an approval for its rival RSV vaccine Abrysvo. Like Arexvy, Pfizer's shot also nabbed an older-adult label but then went on to get a green light as a maternal vaccine to preventRSV in infants, something Arexvy doesn’t have. But the...
One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP);Diversityin clinical trials;Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues. . . ....